Accessibility Menu
Co-Diagnostics logo

Co-Diagnostics(NASDAQ) CODX

Market Cap$7.44MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2017)-99%
5 Year-100%
1 Year-83%
1 Month-54%
$1.54
+9.22%
+0.13Today
Co-Diagnostics last closing stock price
MetricPriceDate
Last closeUSD 1.412026-07-28
Co-Diagnostics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-40.25%USD 2.362026-07-21
1 month-53.92%USD 3.062026-06-26
3 month-7.84%USD 1.532026-04-29
Year to date-72.12%USD 5.062025-12-31
1 year-83.06%USD 8.332025-07-28
3 year-96.44%USD 39.602023-07-28
5 year-99.52%USD 294.902021-07-29
Since inception-99.19%USD 174.302017-07-12

Co-Diagnostics Financials at a Glance

Market Cap

$7.44MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$718.17K

Net Income (TTM)

-$48.50M

EPS (TTM)

-$28.01

P/E Ratio

-0.05

Dividend

$0.00

Beta (Volatility)

1.34 (Average)

Price

$1.54

Volume

822,804.566

Open

$1.47

Previous Close

$1.41

Daily Range

$1.43 - $1.67

52-Week Range

$1.26 - $46.50

Estimated Earnings Date

Aug 14, 2026

CODX News

Foolcom-Featured.png

Co-Diagnostics Sales Plunge 93 Percent

Motley Fool Markets TeamAug 14, 2025
Person in a lab looking through a microscope

Why Co-Diagnostics Stock Slipped Today

Eric VolkmanAug 15, 2022
DNA genetic sequencing biotech

Why Shares of Co-Diagnostics Stock Fell 10% on Tuesday

James HalleyAug 9, 2022
man gets covid test

Why Co-Diagnostics Stock Is Rising Today

Alex CarchidiJul 11, 2022
nasal swab medical test coronavirus getty

Why Co-Diagnostics Is Running Higher Today

Rich DupreyJul 5, 2022
Person in a lab looking through a microscope

Why Co-Diagnostics Trounced the Market on Thursday

Eric VolkmanMay 26, 2022
GettyImages-944545988

Why Co-Diagnostics Stock Tumbled by Nearly 12% Today

Eric VolkmanMar 25, 2022
diagnostics covid getty

Why Co-Diagnostics Is Soaring Today

Rich DupreyMar 15, 2022
Page 1

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Co-Diagnostics

Co-Diagnostics makes tests that help detect diseases like COVID-19 and flu. Its products help doctors, labs, and even individuals find infections quickly. These tests support public health by making disease detection more accessible and affordable.

Products and Services

  • PCR Diagnostic Tests: Detects infectious diseases such as COVID-19, flu, and tuberculosis; 67% of 2025 revenue.
  • Multiplexed Mosquito Tests: Identifies diseases carried by mosquitoes for public health agencies.
  • Genetic Trait Tests: Screens plant and animal DNA for agriculture and research.
  • Portable PCR Platform: Point-of-care and at-home testing device, not yet commercialized.
  • Liquid Biopsy Tools: Supports cancer screening and research applications.

Growth and Expansion

  • Launched joint venture CoSara in India for local manufacturing and sales (2017).
  • Formed CoMira in Saudi Arabia for Middle East/North Africa expansion (2025).
  • Received grants from NIH and Gates Foundation for new test development (2023-2025).
  • Expanded product line to include multiplex respiratory and mosquito-borne disease tests (2020-2025).
  • Entered European and Latin American markets through regulatory approvals and distributors (2020-2025).

What Makes Co-Diagnostics Stand Out

Co-Diagnostics owns its core technology, reducing costs and reliance on third parties. Its tests work on many devices and can detect multiple diseases at once. The company focuses on affordability and access, especially in lower-income regions.

Five Things You Need to Know

  • Revenue was $0.62 million in 2025, down 84% from 2024.
  • Product sales made up 67% of 2025 revenue; grants contributed 33%.
  • International sales were 7% of total revenue in 2025.
  • Net loss was $46.9 million in 2025, up 25% from 2024.
  • Cash and equivalents were $11.9 million at year-end 2025.

Bottom Line

Co-Diagnostics has shifted from pandemic-driven growth to broader disease testing. The company faces financial challenges but continues to develop new diagnostic tools and expand globally.

AI Generated • Apr 16, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

115

CEO

Dwight Howard Egan

Website

co-dx.com

Headquarters

Salt Lake City, UT 84109, US

CODX Financials

Key Financial Metrics (TTM)

Gross Margin

9.49%

Operating Margin

-4447.41%

Net Income Margin

-6753.69%

Return on Equity

-164.92%

Return on Capital

-143.07%

Return on Assets

-225.60%

Earnings Yield

-20.00%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$7.44MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

5.28M

Volume

822.80K

Avg. Volume

5.82M

Financials (TTM)

Gross Profit

$68.17K

Operating Income

-$31.94M

EBITDA

-$49.05M

Operating Cash Flow

-$28.24M

Capital Expenditure

-$750.15K

Free Cash Flow

-$28.99M

Cash & ST Invst.

$8.23M

Total Debt

$2.03M

Co-Diagnostics Performance Analysis

Co-Diagnostics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 34,218,209-65.0%
20232023-12-31USD 991,473-97.1%
20242024-12-31USD 770,048-22.3%
20252025-12-31USD 418,205-45.7%
Co-Diagnostics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30224.0%
Q32025-09-30-10.8%
Q42025-12-3181.5%
Q12026-03-31-44.7%
Co-Diagnostics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -13.57N/A
20232023-12-31USD -36.12166.2%
20242024-12-31USD -37.223.1%
20252025-12-31USD -35.25-5.3%
Co-Diagnostics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-300.7%
Q32025-09-3033.4%
Q42025-12-31-254.9%
Q12026-03-3175.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$145.95K

+190.3%

Gross Profit

-$303.26K

-1157.1%

Gross Margin

-2.08%

N/A

Market Cap

$7.44MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$64.72K

N/A

Employees

115

N/A

Net Income

-$9.14M

-21.3%

EBITDA

-$8.88M

-22.7%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$8.23M

-61.7%

Total Debt

$2.03M

+5.1%

Accounts Receivable

$82.39K

-39.6%

Inventory

$846.12K

-21.9%

Long Term Debt

$1.17M

+14.0%

Short Term Debt

$857.64K

-5.0%

Return on Assets

-2.26%

N/A

Return on Invested Capital

-1.86%

N/A

Free Cash Flow

-$7.99M

+9.6%

Operating Cash Flow

-$7.85M

+10.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ADGMAdagio Medical Holdings, Inc.
$0.42-6.08%
SINTSintx Technologies, Inc.
$1.51-3.21%
XAIRBeyond Air, Inc.
$5.51+0.92%
DWTXDogwood Therapeutics, Inc.
$1.54-0.65%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOFISoFi Technologies
$15.23-0.09%
NVDANvidia
$190.01-0.04%
INTCIntel
$81.92-0.05%
FFord Motor Company
$15.28+0.02%

Questions About CODX

What is the current price of Co-Diagnostics?

Co-Diagnostics is trading at $1.51 per share.

What is the 52-week range for Co-Diagnostics?

Over the past 52 weeks, Co-Diagnostics has traded between $1.26 and $46.50.

How much debt does Co-Diagnostics have?

As of the most recent reporting period, Co-Diagnostics reported total debt of $2.03M.

How much cash does Co-Diagnostics have on hand?

Co-Diagnostics reported $8.23M in cash and cash equivalents in its most recent financial results.

What is Co-Diagnostics’s dividend yield?

Co-Diagnostics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services